Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 DiabetesRury R. Holman, Adrian F. Hernandez, M. Angelyn Bethel et al.|New England Journal of Medicine|2017Cited by 2.1k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trialAdrian F. Hernandez, Lauren B. Cooper, Robert W. Harrison et al.|The Lancet|2018Cited by 1.8k
Medical Therapy for Heart Failure With Reduced Ejection FractionStephen J. Greene, Gregg C. Fonarow, Javed Butler et al.|Journal of the American College of Cardiology|2018Cited by 1.3k
Time to Treatment With Intravenous Tissue Plasminogen Activator and Outcome From Acute Ischemic StrokeJeffrey L. Saver, Lee H. Schwamm, Gregg C. Fonarow et al.|JAMA|2013Cited by 869
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysisM. Angelyn Bethel, Rury R. Holman, Rishi Patel et al.|The Lancet Diabetes & Endocrinology|2017Cited by 591